NZ536111A - Statin therapy for enhancing cognitive maintenance - Google Patents

Statin therapy for enhancing cognitive maintenance

Info

Publication number
NZ536111A
NZ536111A NZ536111A NZ53611103A NZ536111A NZ 536111 A NZ536111 A NZ 536111A NZ 536111 A NZ536111 A NZ 536111A NZ 53611103 A NZ53611103 A NZ 53611103A NZ 536111 A NZ536111 A NZ 536111A
Authority
NZ
New Zealand
Prior art keywords
statin therapy
enhancing cognitive
maintenance
cognitive maintenance
statin
Prior art date
Application number
NZ536111A
Other languages
English (en)
Inventor
Sean Lilienfeld
Elane M Gutterman
Royston John Glasspool
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of NZ536111A publication Critical patent/NZ536111A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrrole Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NZ536111A 2002-04-02 2003-03-28 Statin therapy for enhancing cognitive maintenance NZ536111A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36928502P 2002-04-02 2002-04-02
PCT/EP2003/003324 WO2003082298A1 (en) 2002-04-02 2003-03-28 Statin therapy for enhancing cognitive maintenance

Publications (1)

Publication Number Publication Date
NZ536111A true NZ536111A (en) 2006-03-31

Family

ID=28675573

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ536111A NZ536111A (en) 2002-04-02 2003-03-28 Statin therapy for enhancing cognitive maintenance

Country Status (21)

Country Link
EP (1) EP1492539B1 (cg-RX-API-DMAC7.html)
JP (1) JP2005525391A (cg-RX-API-DMAC7.html)
KR (1) KR100986194B1 (cg-RX-API-DMAC7.html)
CN (1) CN100528164C (cg-RX-API-DMAC7.html)
AT (1) ATE331523T1 (cg-RX-API-DMAC7.html)
AU (1) AU2003226753B2 (cg-RX-API-DMAC7.html)
BR (1) BR0308293A (cg-RX-API-DMAC7.html)
CA (1) CA2480275C (cg-RX-API-DMAC7.html)
CY (1) CY1105545T1 (cg-RX-API-DMAC7.html)
DE (1) DE60306503T2 (cg-RX-API-DMAC7.html)
DK (1) DK1492539T3 (cg-RX-API-DMAC7.html)
EA (1) EA013069B1 (cg-RX-API-DMAC7.html)
ES (1) ES2268393T3 (cg-RX-API-DMAC7.html)
IL (2) IL164317A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA04009535A (cg-RX-API-DMAC7.html)
NO (1) NO20044698L (cg-RX-API-DMAC7.html)
NZ (1) NZ536111A (cg-RX-API-DMAC7.html)
PL (1) PL211160B1 (cg-RX-API-DMAC7.html)
PT (1) PT1492539E (cg-RX-API-DMAC7.html)
UA (1) UA79605C2 (cg-RX-API-DMAC7.html)
WO (1) WO2003082298A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1603548A4 (en) * 2003-02-05 2007-10-10 Myriad Genetics Inc METHOD AND COMPOSITION FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES
EP1737539A1 (en) * 2004-04-14 2007-01-03 Warner-Lambert Company LLC Therapeutic combination for treatment of alzheimers disease
EP1604686A1 (en) * 2004-06-08 2005-12-14 Axonyx, Inc. Use of phenserine and a HMG CoA reductase inhibitor for delaying Alzheimer's disease progression
GB0607946D0 (en) * 2006-04-21 2006-05-31 Minster Res The Ltd Mono and combination therapy
AU2007299726A1 (en) * 2006-09-22 2008-03-27 Braincells, Inc. Combination comprising an HMG-COA reductase inhibitor and a second neurogenic agent for treating a nervous system disorder and increasing neurogenesis
TWI432195B (zh) 2007-10-03 2014-04-01 Kowa Co 神經細胞死亡抑制劑
US20160303146A1 (en) * 2013-12-13 2016-10-20 David A. TABACZYNSKI Inhibition of isoprenoid biosynthetic pathways to treat neuroinflammatory disorders

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW506836B (en) * 1996-06-14 2002-10-21 Janssen Pharmaceutica Nv Fast-dissolving galanthamine hydrobromide tablet

Also Published As

Publication number Publication date
PL211160B1 (pl) 2012-04-30
CN100528164C (zh) 2009-08-19
PT1492539E (pt) 2006-11-30
KR100986194B1 (ko) 2010-10-07
DE60306503T2 (de) 2007-06-21
DK1492539T3 (da) 2006-10-30
PL371551A1 (en) 2005-06-27
CY1105545T1 (el) 2010-07-28
IL164317A0 (en) 2005-12-18
AU2003226753B2 (en) 2007-06-28
AU2003226753A1 (en) 2003-10-13
NO20044698L (no) 2004-10-29
ATE331523T1 (de) 2006-07-15
EA200401295A1 (ru) 2005-02-24
DE60306503D1 (de) 2006-08-10
HK1079688A1 (zh) 2006-04-13
JP2005525391A (ja) 2005-08-25
CN1642555A (zh) 2005-07-20
MXPA04009535A (es) 2005-01-25
EP1492539B1 (en) 2006-06-28
UA79605C2 (en) 2007-07-10
EP1492539A1 (en) 2005-01-05
ES2268393T3 (es) 2007-03-16
BR0308293A (pt) 2004-12-28
KR20040096608A (ko) 2004-11-16
IL164317A (en) 2010-04-29
EA013069B1 (ru) 2010-02-26
CA2480275C (en) 2011-08-16
WO2003082298A1 (en) 2003-10-09
CA2480275A1 (en) 2003-10-09

Similar Documents

Publication Publication Date Title
MXPA05008406A (es) Compuestos de amida tri(ciclo)-sustituida.
MXPA04005790A (es) Compuestos y usos de los mismos para reducir la actividad de la lipasa sensible a la hormona.
GEP20094759B (en) Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors
AU7031500A (en) Therapeutic quinazoline compounds
WO2004006858A3 (en) Compounds, compositions, and methods employing same
IL195723A (en) Use of p53 inhibitors for the preparation of medicament
UA84025C2 (en) Normal;heading 1;heading 2;2-(QUINOXALIN-5-YLSULFONYLAMINO)-BENZAMIDE COMPOUNDS AS CCK2 MODULATORS
ATE299022T1 (de) Verwendung von cyclopamine zur herstellung eines arzneimittels zur behandlung von psoriasis
PL1654253T3 (pl) Podstawione pochodne 3-pirolidynoindolu
MXPA04004355A (es) Tratamiento de combinacion que comprende zd6474 y un taxano.
MXPA05003253A (es) Nuevos derivados de pirimidinamida y el uso de los mismos.
PL378369A1 (pl) Sposób leczenia mdłości, wymiotów, nudności lub ich dowolnej kombinacji
GB9716879D0 (en) Treatment of attention deficit disorders
PL366800A1 (en) Tablet comprising cetirizine and pseudoephedrine
GB0020504D0 (en) Therapeutic method
AP9801202A0 (en) Atropisomers of 3-heteroaryl-4(3H)-quinazolinones.
CA2370834A1 (en) Use of saredutant and the pharmaceutically acceptable salts thereof to produce medicaments used to treat or prevent mood disorders, adjustment disorders or mixed anxiety-depression disorders
GB0215526D0 (en) Anticancer compounds
MY129643A (en) Tablet comprising cetirizine and pseudoephedrine
TW200626137A (en) Preventive or therapeutic agent for sleep disorder
PL367401A1 (en) Utilization of buprenorphine in urinary incontinence therapy
IL164317A0 (en) Statin therapy for enhancing cognitive maintenance
IL170519A (en) Use of fenofibrate or pharmaceutically acceptable salt thereof, orlistat and pharmaceutically acceptable carrier in the manufacture of medicaments for the treatment of obesity and pharmaceutical compositions containing them
SE0101258D0 (sv) Treatment of low back pain and whiplash associated disorder
DE60215219D1 (de) Verwendung von darifenacin zur behandlung des harndrangs

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 28 MAR 2016 BY CPA GLOBAL

Effective date: 20130214

LAPS Patent lapsed